Owl Posting

For a more technical dive into startups that have been chugging along with AI in pathology for ~decade, check out this:

https://www.owlposting.com/p/what-happened-to-pathology-ai-companies

> One pathology AI founder told me that it wasn’t hospitals or diagnostic labs that showed the most promise. It was R&D groups within Big Pharma. Those scientists and executives wanted new tooling. They were often sitting on massive internal datasets, had real budget allocated to experimental tech, and — critically — had a clear ROI if your model helped shave months off a study or more precisely target the right patient cohort. Most importantly, pharma didn’t care as much about the regulatory headaches, as they weren’t using your model to diagnose patients

Yes, mRNA vaccines are promising for many but not all cancer types, and there are many ongoing clinical trials. There's also a lot we yet don't know about how to design them.

Here's a great blog post on this, "How to build a cancer vaccine, and whether they will work this time": https://www.owlposting.com/p/how-to-build-a-cancer-vaccine-and

Here's the blog post I wrote on personalized mRNA vaccines: https://hedonicescalator.substack.com/p/did-paul-conyngham-really-use-ai